EP194: Monitoring Medications With Dr Begg

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Podcast Summary Introduction Dr. Warrick Bishop, a practicing cardiologist and author, hosts this episode with his colleague Dr. Alistair Begg, also a cardiologist from Adelaide. The episode focuses on the comprehensive monitoring protocols cardiologists implement when starting patients on cardiac medications, including cholesterol-lowering drugs, blood pressure medications, and rhythm management therapies. Key Takeaways: Blood tests are essential for monitoring both the effectiveness of cardiac medications and their potential side effects, particularly for drugs like statins that can affect muscle and liver function. Creatinine kinase (CK) and liver function tests (LFTs) should be monitored in patients on statins, but baseline measurements are important since normal CK levels vary by individual and can be elevated by exercise, dehydration, or physical activity. A CK elevation requires clinical judgment—mild elevations may be monitored without stopping medication if the drug's benefits outweigh the risks, while significant elevations (such as over 2,500-3,000) warrant immediate investigation and potential medication discontinuation. ACE inhibitors and angiotensin-2 blockers used for blood pressure management require periodic kidney function monitoring, as they can potentially deteriorate kidney function, particularly in older patients. Diuretics can affect potassium levels and cause dehydration, necessitating regular blood test monitoring alongside blood pressure measurement. 24-hour ambulatory blood pressure monitoring is valuable for detecting white coat hypertension and determining whether patients actually require medication before starting treatment. Rhythm management medications require ECG monitoring to detect drug-induced changes in heart rhythm patterns, particularly monitoring the QT interval for drugs like sotalol and characteristic changes for flecainide. Amiodarone requires regular thyroid and liver function testing, as approximately 25% of patients in some regions experience thyroid abnormalities while taking this medication. Cardiologists should involve patients in medication decisions by discussing both benefits and risks, which increases patient engagement and medication adherence. Effective medication monitoring involves dual tracking: assessing therapeutic effectiveness (cholesterol levels, blood pressure control, rhythm stability) and surveilling for potential adverse effects through blood tests and ECG findings.